Patents Examined by Kimberly Chong
  • Patent number: 10934550
    Abstract: Immunogenic modulators and compositions comprising oligonucleotide agents capable of inhibiting suppression of immune response by reducing expression of one or more gene involved with an immune suppression mechanism.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 2, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Alexey Wolfson, Alexey Eliseev, Taisia Shmushkovich
  • Patent number: 10925973
    Abstract: In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: February 23, 2021
    Inventors: Jindrich Henry Kopecek, Jiyuan Yang
  • Patent number: 10927377
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: February 23, 2021
    Inventor: Susan M. Freier
  • Patent number: 10920224
    Abstract: This invention is in the field of molecular biology, gene expression, functional genomics, and bioinformatics and relates to novel RNA and related structures and methods of use thereof that enables modulation of gene expression and preservation of particular transcriptome targets. The invention contemplates various applications of RNA sequences derived from the genomic RNA of flaviviruses (FVs) and the application of such features in combination with heterologous sequences.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: February 16, 2021
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Jeffrey S. Kieft, Erich G. Chapman, David A. Costantino, Jay R. Hesselberth, Andrea MacFadden, Benjamin Akiyama
  • Patent number: 10912736
    Abstract: Provided are a method of delivering target materials into extracellular vesicles including exposing the target materials and the extracellular vesicles to extracorporeal shockwaves, a method of preparing target material-introduced extracellular vesicles, extracellular vesicles prepared by the method, drug delivery vehicles including extracellular vesicles, and a method of delivering target materials into cells. The present disclosure exposes extracellular vesicles derived from natural organisms such as animal cells, plant cells, and microorganisms including bacteria and eukaryotic bacteria as well as artificially produced extracellular vesicles to extracorporeal shockwaves extracellularly. Thus, the high-level energy extracorporeal shockwaves can be used to deliver the target material into the extracellular vesicle efficiently. When treating with extracorporeal shockwaves, the ability of target material-introduced extracellular vesicles to incorporate into target cells also increases.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: February 9, 2021
    Inventors: Kihwan Kwon, Jihwa Chung, Kyounghwa Kim
  • Patent number: 10905708
    Abstract: Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: February 2, 2021
    Inventors: Takahiro Ochiya, Tomohiro Fujiwara
  • Patent number: 10900036
    Abstract: This invention relates to polycomb-associated RNAs, libraries and fragments of those RNAs, inhibitory nucleic acids and methods and compositions for targeting RNAs, and methods of use thereof.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 26, 2021
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Michael Rosenberg, Barry Kesner
  • Patent number: 10900035
    Abstract: Three-way junction (3WJ) RNA scaffolds derived from phi29, M2, SF5, and GA1 pRNAs and which have high stability are described. The pRNA 3WJ scaffolds can be used to form compounds, conjugates, compositions, and nanoparticles for delivery of active agents for therapeutic and/or diagnostic functions.
    Type: Grant
    Filed: February 26, 2017
    Date of Patent: January 26, 2021
    Assignees: The Board of Regents of the University of Oklahoma
    Inventors: Alyssa C. Hill, Susan J. Schroeder
  • Patent number: 10898590
    Abstract: A method for delivery of a therapeutic agent to a nervous tissue. In particular, a method of delivering a therapeutic agent to a nervous tissue protected by the brain-blood barrier or meninges is disclosed. The method for delivery allows delivery of a therapeutic agent to a nervous tissue with high efficiency. In addition, the delivery method of a therapeutic agent to a nervous tissue is safe since it has lower side effects such as nervous damage than a method of administering a therapeutic agent directly to a nervous tissue.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 26, 2021
    Inventors: Sujeong Kim, Heonsik Choi, Kyoungbaek Choi, Minjung Kim, Yejin Kwon, Hyeonyoul Lee, Minju Kim, Daewook Kim, Jangjoon Park, Yeomoon Sim
  • Patent number: 10898522
    Abstract: A method of preventing the development of GvHD or reducing the severity of GvHD in a mammalian subject receiving an allogeneic hematopoietic stem cell (HSC) transplant includes administering to the subject a pharmaceutical composition comprising an active agent that inhibits the biological activity or expression of hypoxia-inducible factor-1a (HIF-1a) or hypoxia-inducible factor-2a (HIF-2a), wherein the active agent is administered in an amount effective for preventing or reducing the severity GvHD in the subject.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: January 26, 2021
    Assignee: Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Yin Wang
  • Patent number: 10889813
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: January 12, 2021
    Inventor: Gregory Hinkle
  • Patent number: 10888577
    Abstract: There is disclosed herein methods, uses and systems for the detection, diagnosis, prognosis, treatment or prevention of a disease or condition comprising cartilage degeneration in a subject that is in need thereof. The methods comprise the use, inhibition or measurement of at least one of miR-181 a-5p and miR-4454, in the subject.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: January 12, 2021
    Inventors: Mohit Kapoor, Akihiro Nakamura, Raja Rampersaud
  • Patent number: 10881743
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: January 5, 2021
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Patent number: 10876117
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 29, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 10869880
    Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: December 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Zhenyu Zhong
  • Patent number: 10870850
    Abstract: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions containing chemically modified RNAi agents according to aspects of the present invention (including pharmaceutical compositions) and kits containing the same are also provided.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: December 22, 2020
    Assignee: SOMAGENICS, INC.
    Inventors: Qing Ge, Brian H. Johnston, Mark A. Behlke, Heini Ilves, Anne Dallas
  • Patent number: 10865415
    Abstract: Provided are a dsRNA construct of an orphan G-protein-coupled receptor GPR160 gene related to prostate cancer and the use thereof, wherein the dsRNA construct of the GPR160 gene and a composition thereof can prevent or treat prostate cancer.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 15, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Caihong Zhou, Xinchuan Dai, Mingwei Wang
  • Patent number: 10857174
    Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: December 8, 2020
    Inventors: Prakash Ambady, Jeffrey Wu, Edward Neuwelt
  • Patent number: 10849841
    Abstract: This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase level or activity; methods of stimulating hair growth, comprising the step of contacting a subject with a compound or composition capable of increasing or decreasing the activity or level of a target gene of the present invention, or with a protein product of the target gene or an analogue or mimetic thereof; and methods of testing for AGA and evaluating therapeutic methods thereof, comprising measuring PGD2 levels.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: December 1, 2020
    Inventors: George Cotsarelis, Luis Garza
  • Patent number: 10851375
    Abstract: The invention relates to inhibitory nucleic acids and rAAV-based compositions, methods and kits useful for treating Amyotrophic Lateral Sclerosis.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: December 1, 2020
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Robert H. Brown, Jr.